Urologic Oncology: Seminars and Original Investigations
Original articleFGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer
Introduction
Prostate cancer is a leading cause of cancer-related morbidity and mortality in men in most industrialized countries [1]. Although the precise mechanisms of prostate cancer (PCa) progression and metastasis are still poorly understood, a number of findings suggest that these processes are not strictly tumor cell-specific but also shaped by strong influences of the tumor stroma. One growth factor family that has been extensively studied in this context are fibroblast growth factors (FGFs) [2], [3], [4], [5].
Numerous in vitro and in vivo results underscore a crucial role of FGFs and their receptors in prostate carcinogenesis and tumor progression [3], [6], [7]. The human FGF gene family consists of over 20 members that encode secreted polypeptides. FGFs exert their activities mainly through 4 conserved transmembrane tyrosine kinase receptors (FGFR1–4). Downstream signaling events are complex and mainly consist of activation of the phosphatidylinositol 3-kinase (PI3K)/AKT, mitogen-activated kinase, phospholipase Cγ (PLCγ) and signal transducers and activators of transcription signaling pathways. FGFs are mitogenic, they increase cell survival and migration and stimulate angiogenesis [2].
There is compelling evidence that in particular upregulation of FGF-2 (basic FGF) plays an important role in prostate carcinogenesis [3], [4]. A major source of FGF-2 in PCa is the stromal cell compartment as well as the extracellular matrix [6]. FGF-2 can also be produced by PCa cells to function in an paracrine or autocrine fashion [6]. A knock-out of FGF-2 was found to delay tumor progression in the transgenic adenocarcinoma of the mouse prostate model [8]. In addition, dovitinib, a small molecule multi-kinase inhibitor that exerts antitumoral activities through inhibition of the FGF and PDGF signaling axis, respectively, has shown promising clinical effects in FGFR-driven PCa patient-derived xenograft (PDX) models and in PCa patients with bone metastasis [9].
Prostate cancer progression is characterized by increasing genomic instability including numerical chromosomal aberrations (aneuploidy) as well as structural chromosomal changes [10], [11]. Although aneuploidy is typically a result of mitotic defects, structural chromosomal instability requires DNA breaks that are left unrepaired or repaired in an erroneous fashion [12].
In the present report, we demonstrate that exogenous FGF-2 can provoke numerical chromosomal imbalances as well as DNA breakage both in vitro and in a PDX mouse model. In addition, we show that stroma-associated FGF-2 is a negative prognostic factor in high-risk PCa thus underscoring the important role of the tumor stroma in malignant progression. Our findings highlight that PCa cell genomes can be shaped by factors derived from the tumor stroma and that targeting these processes represents a promising therapeutic option [5].
Section snippets
Cell culture and drug treatments
LNCaP and PC-3 PCa cells were provided by CLS (Eppelheim, Germany) and maintained as recommended by the distributor. For experiments, cells were treated with 10 ng/ml biologically active recombinant FGF-2 (rFGF-2; NovActive, NBC1–21335, Novus Biologicals, Littleton, CO; migrating at 23 kDa and 26 kDa in SDS-PAGE) for 72 hour or dH2O used as solvent control. Cells were treated with 1 µM dovitinib (TKI-258; Selleck Chemicals, Houston, TX) for 72 hour or 0.1% dimethyl sulfoxide (DMSO) as solvent
FGF-2 stimulates centrosome amplification and aberrant mitoses in vitro and in vivo
Centrosomes are the major microtubule-organizing centers in most mammalian cells and aberrant centrosome numbers, which can lead to mitotic defects and chromosome segregation errors, are a common finding in PCa [17], [18]. We have previously shown that FGF-2 can stimulate aberrant centrosome duplication and mitotic defects in vitro [19]. However, whether these alterations can occur in vivo and result in chromosomal imbalances has not been tested. We hence first corroborated the role of FGF-2 in
Discussion
In the present study, we report a number of novel findings centered on FGF-2, a well-known growth factor involved in prostate carcinogenesis. We first confirm and extend our previous findings [19] by showing that FGF-2 can not only disrupt mitotic fidelity by inducing an abnormal duplication of centrosomes but that this process in fact leads to numerical chromosomal imbalances. Furthermore, we show that FGF-2 can provoke DNA breakage thereby contributing to genomic instability in PCa cells
Acknowledgements
We would like to thank Geraldine Rauch for advice on statistics and the tumor documentation team of the Department of Urology for patient data collection. We are grateful to the tissue bank of the National Center for Tumor Diseases Heidelberg for tissue procurement and TMA construction. This work was supported by the Medical Faculty Heidelberg and by the MD Anderson Cancer Center Global Academic Program Sister Institution Network Fund (SINF).
References (35)
- et al.
Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications
Eur Urol
(2003) - et al.
Integrative genomic profiling of human prostate cancer
Cancer Cell
(2010) - et al.
A cross-platform public domain PC image-analysis program for the comet assay
Mutat Res
(2003) - et al.
DNA aneuploidy in prostatic adenocarcinoma: a frequent event as shown by fluorescence in situ DNA hybridization
Hum Pathol
(1994) - et al.
Punctuated evolution of prostate cancer genomes
Cell
(2013) - et al.
Integrative clinical genomics of advanced prostate cancer
Cell
(2015) - et al.
Prognostic significance and functional role of CEP57 in prostate cancer
Transl Oncol
(2015) - et al.
EGF-induced centrosome separation promotes mitotic progression and cell survival
Dev Cell
(2013) - et al.
Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation
Cancer Cell
(2012) - et al.
Cancer statistics, 2013
CA Cancer J Clin
(2013)
Fibroblast growth factor signalling: from development to cancer
Nat Rev Cancer
Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer
Clin Cancer Res
Targeting fibroblast growth factor pathways in prostate cancer
Clin Cancer Res
The role of fibroblast growth factors and their receptors in prostate cancer
Endocr Relat Cancer
Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype
J Pathol
Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer
Cancer Res
Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases
Sci Transl Med
Cited by (13)
Experimental in vitro, ex vivo and in vivo models in prostate cancer research
2023, Nature Reviews UrologyFibroblast growth factors signaling in bone metastasis
2020, Endocrine-Related Cancer
- 1
Co-first authors.